Arsenal of antibiotics not being restockedDispute over rules for approving new drugs stalls production even as concern rises over deadly resistant bacteria
excerpt:Quote:
Drug companies are abandoning the antibacterial business, citing high development costs, low return on investment and, increasingly, a nearly decade-long stalemate with the Food and Drug Administration over how to bring new antibiotics to market.
Soon, doctors fear, we could be defenseless against bacteria that can resist all existing antibiotics, which would mean more victims like Simon, dead from a staph infection that drugs used to conquer easily.
Read entire article here: http://www.chicagotribune.com/health/ct ... 7492.story